- Ticker
- ABEO
- Price
- 2.40
- Stock movement down
- -0.05 (-2.04%)
- Company name
- Abeona Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 41.22M
- Ent value
- 58.84M
- Price/Sales
- 9.48
- Price/Book
- 2.67
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 727.59%
- 3 year return
- 4.06%
- 5 year return
- -30.24%
- 10 year return
- -20.25%
Last updated: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
March 29, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
December 1, 2022
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABEO does not pay dividends or no data was received
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 14, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 3, 2022
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.48 |
| Price to Book | 2.67 |
| EV to Sales | 13.54 |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
November 3, 2022
iO Charts is a Seeking Alpha partner
Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
October 19, 2022
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.18M |
| EPS (TTM) | -13.28 |
| FCF per share (TTM) | -7.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.35M |
| Gross profit (TTM) | 4.00M |
| Operating income (TTM) | -84.63M |
| Net income (TTM) | -85.25M |
| EPS (TTM) | -13.28 |
| EPS (1y forward) | -1.79 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 91.95% |
| Operating margin (TTM) | -1947.33% |
| Profit margin (TTM) | -1961.64% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.73M |
| Net receivables | 1.05M |
| Total current assets | 25.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 38.76M |
| Accounts payable | 1.75M |
| Short/Current long term debt | 8.29M |
| Total current liabilities | 12.60M |
| Total liabilities | 23.35M |
| Shareholder's equity | 15.41M |
| Net tangible assets | 15.41M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -46.16M |
| Capital expenditures (TTM) | 2.91M |
| Free cash flow (TTM) | -49.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -553.12% |
| Return on Assets | -219.95% |
| Return on Invested Capital | -495.00% |
| Cash Return on Invested Capital | -284.93% |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
October 4, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
October 3, 2022
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.46 |
| Daily high | 2.49 |
| Daily low | 2.38 |
| Daily Volume | 49K |
| All-time high | 47188.00 |
| 1y analyst estimate | 21.33 |
| Beta | 1.25 |
| EPS (TTM) | -13.28 |
| Dividend per share | - |
| Ex-div date | 22 Jul 2022 |
| Next earnings date | 29 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ABEO | S&P500 | |
| Current price drop from All-time high | -99.99% | -17.92% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -92.06% | -11.51% |
| Avg time to new high | 406 days | 13 days |
| Max time to new high | 7600 days | 1805 days |
The following slide deck was published by Abeona Therapeutics Inc.
August 17, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
August 11, 2022
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
41.22M
Marketcap category
Small-cap
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Employees
90
Investor relations
-
SEC filings
CEO
Joao Siffert
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
July 20, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
July 5, 2022
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 19, 2022
iO Charts is a Seeking Alpha partner
Abeona Therapeutics Inc.'s (ABEO) CEO Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
May 17, 2022
iO Charts is a Seeking Alpha partner
COMPANY NEWS
All newsPress releases
We can readily understand why investors are attracted to unprofitable companies. For example, although...
March 31, 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
March 29, 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
March 24, 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
March 16, 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
March 14, 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
November 14, 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
November 8, 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
November 3, 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
November 3, 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
November 3, 2022
Next page
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 17, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
May 13, 2022
iO Charts is a Seeking Alpha partner